UPDATE 1-Teva Pharm eyes more acquisitions after buying Allergan's generics business

JERUSALEM, Aug 4 (Reuters) - Teva Pharmaceutical Industries will remain in the hunt for more acquisitions after completing a deal to buy Allergan's generics business for $40.5 billion this week.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.